ArticleScientific reports2025
Establishment and evaluation of an immortalized dzo kidney cell line.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Immortalized cell lines constructed through transfecting genes such as the hTERT and the SV40-LT provide stable cellular resources for both scientific exploration and industrial implementation. Although advancements have been documented in the establishment of immortalized cell types, research on immortalization of specialized animal cell types remains an underexplored domain. To explore the applicable value of the dzo, a yak-cattle hybrid endemic to northwestern China, and develop potential cell substrates that can be used for the production of BVDV vaccines, this study adopts an immortalization strategy with the hTERT and SV40-LT genes to construct an immortalized dzo kidney cell line. This study employed a lentiviral vector system to stably integrate SV40-LT into dzo renal cells, successfully generating the immortalized NBLS cell line. Compared to liposome-mediated transfection, lentiviral delivery demonstrated superior gene transfer efficiency through high integration capacity and broad tropism. NBLS cells maintained robust proliferation (viability > 90%), normal cell cycle distribution, and diploid karyotype (2n = 60) through 50 passages, whereas hTERT-only transfectants exhibited viability decline below 70% after passage 10. Functional validation revealed NBLS cells displayed enhanced BVDV susceptibility (lgTCID50 = 10^- 6.59/0.1 mL), with tenfold increased sensitivity compared to primary counterparts. The results will provide potential materials for BVDV vaccine production and species-specific cellular models for investigating plateau-adapted disease resistance mechanisms and screening novel vaccine antigens.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.